Association between RAS gene polymorphisms (ACE I/D, AGT M235T) and Henoch-Schönlein purpura in a Turkish population

Sinem Nalbantoglua,*, Yılmaz Tabelb, Seygi Mirc, Erkin Serdaroğlu and Afıg Berdelia

aMolecular Medicine Laboratory, Children’s Hospital, Faculty of Medicine, Ege University, Bornova, Izmir, Turkey
bDepartment of Pediatrics, Faculty of Medicine, İnönü University, Malatya, Turkey
cDivision of Pediatric Nephrology, Department of Pediatrics, Faculty of Medicine, Ege University, Bornova, Izmir, Turkey
dİzmir Dr. Behcet Uz Children’s Hospital, Izmir, Turkey

Abstract. Henoch-Schönlein purpura (HSP) is a small-vessel vasculitis of autoimmune hypersensitivity, and renin-angiotensin system (RAS) regulates vascular homeostasis and inflammation with activation of cytokine release. Thus, we aimed to investigate the association between HSP and ACE I/D and AGT M235T polymorphisms. Genotyping was determined by allele specific PCR and PCR-RFLP. We obtained a significant difference in genotype distribution (p = 0.003) and allele frequencies (p < 0.001) of ACE I/D polymorphism between patients and controls, while no significant association was detected in genotype distribution (p > 0.05) and allele frequencies (p > 0.05) of the AGT M235T polymorphism. Risk assessment showed significant risk for HSP in the subjects both with the ID + DD genotype (p = 0.019, OR: 2.288, 95% CI: 1.136–4.609) and D allele (OR: D vs. I: 2.0528, 95% CI: 1.3632–3.0912, p = 0.001) while no significant risk was obtained for HSP in the subjects both with the MT + TT genotype (p = 0.312, OR: 1.3905, 95% CI: 0.7326–2.6391) and T allele (OR: T vs. M: 1.065, 95% CI: 0.729–1.557, p = 0.743). Furthermore, when patients were stratified by the presence of certain systemic complications of HSP, no significant association was detected with ACE I/D, and AGT M235T polymorphisms. Our findings suggest that ACE I/D polymorphism is significantly associated with HSP susceptibility.

Keywords: Henoch-Schönlein purpura (HSP), ACE I/D, AGT M235T, Single Nucleotide Polymorphism (SNP), organ involvement, Genotype-phenotype correlation

1. Introduction

Henoch-Schönlein purpura (HSP) is a rare, non-thrombocytopenic, leukocytoclastic, IgA mediated small-vessel vasculitis of autoimmune hypersensitivity [1]. HSP typically involves small vessels, and mainly affects skin, joints, gastrointestinal (GI) tract, and kidneys some of which progress to renal insufficiency especially in the adulthood. Rare complications of HSP include central and peripheral nervous system and pulmonary complications [2–4]. Immune and inflammatory response activation is a common feature of systemic vasculitis, and HSP is the result of a complex series of inflammatory and immunologic processes. Previously, important roles of pro-inflammatory cytokines and the renin-angiotensin system (RAS) components were shown on HSP pathogenesis [5,6]. RAS
is a multifactorial hormonal system and major mediator in the regulation of sodium homeostasis, blood pressure, body fluid balance, and inflammation [7,8]. Cloned and identified genes encoding RAS include renin [8], angiotensin converting enzyme gene-ACE [9], angiotensinogen gene-AGT [10], angiotensin I, angiotensin II, angiotensin II type 1 (AT1R) and type 2 (AT2R) receptor gene [11]. ACE gene is chromosomally located at 17q23.3 and comprises 26 exons spanning 26 kb of genomic DNA [12], and is mostly expressed in vascular endothelium, lung, kidney, heart and testes [13]. AGT gene is located on chromosome 1q42.2 comprising 5 exons, and express pre-angiotensinogen or angiotensinogen precursor protein in the liver. AGT is cleaved by renin and inactive angiotensin I is produced. ACE catalyzes the conversion of angiotensin I into a physiologically active major effector peptide molecule angiotensin II, and inactivation of bradykinin [14]. Further, angiotensin II shows its physiological function by binding to AT1R and AT2R [8]. Functional effects of RAS gene polymorphisms on transcription and circulating enzyme levels have been mostly identified in the pathogenesis of cardiovascular and renal diseases, later, effects of this system components were associated with susceptibility or severity of autoimmune inflammatory conditions [15, 20]. So far, functionally relevant polymorphisms of this family have included 287 bp Alu repetitive sequence insertion/deletion (I/D) polymorphism in intron 16 of ACE [16], T174A and M235T polymorphisms of AGT [10], and A1166C polymorphism of AGT1R gene [11]. Effects of ACE I/D polymorphism were investigated in ischemic heart disease [17], SLE [18], malignant vascular injury [19], IgA nephropathy [21] and renal injury [22] in different ethnicities. Several SNPs (A-5466C, T-3892C, A-240T, C1237T, G2215A and A2350C) of the ACE gene were also previously related to the risk of certain autoimmune diseases such as essential hypertension [23], left ventricular hypertrophy [24], IgA nephropathy [25], and diabetic nephropathy [26]. DD genotype of ACE I/D polymorphism was previously associated with higher tissue and plasma ACE levels and increased ACE activity in the vessel wall. Furthermore, T allele of the AGT M235T polymorphism was associated with a higher plasma angiotensinogen level [27]. Higher ACE levels lead to an increased conversion of angiotensin I to angiotensin II resulting in vascular inflammation including monocyte adhesion, activation with cytokine release, T-lymphocyte metabolism, and vascular impairment involving neointimal proliferation, vasospasm, platelet activation, myocyte proliferation. Notably, inflammatory cells in particular monocytes/macrophages/T lymphocytes present at inflammatory sites produce high levels of all components of RAS, and vascular RAS regulates vascular homeostasis and inflammation with activation of cytokine release [28–30]. Furthermore, role of angiotensin II has been shown in renal tubular and mesangial cell proliferation in renal disease [31]. Therefore, RAS gene polymorphisms seem to be particularly biologically and clinically relevant to HSP susceptibility which occur due to vasculitis of the small blood vessels, and endothelial cell activation [32]. In this study, we examined the association between HSP susceptibility in Turkish patients and the biologically important ACE I/D and AGT M235T polymorphisms of these key components of RAS.

2. Subjects and methods

Present case-control study comprised 139 clinically diagnosed HSP (77 males/62 females; ages range from 2 to 17 years; female/male ratio was 1.2:1) patients at the department of Pediatric Nephrology in Ege University Faculty of Medicine. The ethnically matched healthy control individuals (ages range from 18 to 45 years; with no renal, vasculitic, or allergic diseases and no vasculitis/rheumatologic and other kidney disease history in family) included 72 healthy individuals for the ACE gene mutation analysis while fifteen more healthy individuals whose blood samples were later obtained were added up to this group (n = 87) for the AGT gene mutation analysis. Control group was chosen from adults because of the lower risk of HSP occurrence older than 20 years old. Criteria defined by the American Rheumatology College (ACR) were used for diagnosis and classification of HSP [33]. The procedures were in accordance with the ethical standard for human experimentation established by the Declaration of Helsinki of 1975, revised 1983. The study was approved by the Ethic Committee of Ege University, and detailed consent forms were signed by patients/parents.

2.1. Genomic DNA isolation

Genomic DNA was isolated from peripheral blood leukocytes using a QIAamp DNA Blood Isolation kit (Qiagen GmbH, Hilden, Germany). A Thermo Scientific NanoDrop spectrophotometer (Wilmington, USA) was used to determine the extracted DNA concentration. The quality assessment of the extracted DNA was determined by 2% agarose gel electrophoresis.
2.2. Genotyping of ACE I/D and AGT M235T polymorphisms

The ACE (NM_000789.3/NP_000780.1) gene I/D polymorphism was determined by allele specific Polymerase Chain Reaction (PCR) assay [34]. The 25 μl PCR reaction mixture contained: one microliter (100 ng) of genomic DNA was added to amplification buffer containing 20 mM Tris (pH 8.3), 50 mM KCl, 1.5 mM MgCl₂, 0.2 mM each of dATP, 2’-deoxycytidine 5’-triphosphate, dGTP, 2’-deoxythymidine 5’-triphosphate, 10 pmol of each primer, and 1.0 U of platinum Taq DNA polymerase (Invitrogen, Paisley, UK). The DNA was amplified by cycling at 94°C for 1 min, 55°C for 1 min, and 72°C for 1.5 min (GeneAmp 9700). After 35 cycles, the reaction was extended for an additional 10 min at 72°C. The oligonucleotide sequences of the primers were as follows:

F 5’-CTGGAGAGCCACTCCCATCCTTTCT-3’
R 5’-GACGGGCTCATCATCCGTACAGAT-3’.

The PCR products were separated by 2% agarose gel electrophoresis, and 490 bp with insertion (I allele) and 190 bp with deletion (D allele) were visualized with ethidium bromide staining in the UVP BioDoc-It System Biolmaging Systems (Fig. 1) (Upland, Calif., USA).

The AGT gene (NM_000029.3/NP_000020.1) M235T polymorphism was determined by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) assay. The 25 μl PCR reaction mixture contained: one microliter (100 ng) of genomic DNA was added to amplification buffer containing 20 mM Tris (pH 8.3), 50 mM KCl, 1.5 mM MgCl₂, 0.2 mM each of dATP, 2’-deoxycytidine 5’-triphosphate, dGTP, 2’-deoxythymidine 5’-triphosphate, 10 pmol of each primer, and 1.0 U of platinum Taq DNA polymerase (Invitrogen, Paisley, UK). The DNA was amplified by cycling at 94°C for 1 min, 55°C for 1 min, and 72°C for 1.5 min (GeneAmp 9700). After 35 cycles, the reaction was extended for an additional 10 min at 72°C. The oligonucleotide sequences of the primers were as follows:

F 5’-CGTTTTTGTCAGGCTCCTCTCTCTTCTTTCC-3’
R 5’-CAGGGGCTGTCCACACTGACACC-3’.
Table 1  
Demographic characteristics and clinical manifestations of a series of patients with HSP

|                          | n (%)          |
|--------------------------|----------------|
| Children ages range from 2 to 17 years | 139 (100)      |
| Male/Female              | 77/62          |
| Age at disease onset, months: mean ± SD | 8.6 ± 3.1/ ranges between 18–45 |
| Duration of follow-up mean ± SD       | 8.2 ± 7.5 months |
| Cutaneous involvement; palpable purpura and/or maculopapular rash | 139 (100) |
| Joint involvement; arthralgia and/or arthritis | 79 (56.8) |
| Gastrointestinal manifestations | 64 (43.8) |
| Hypertension              | 6 (4.3)        |
| Central nervous system (CNS) involvement | 1 (0.7) |
| Renal manifestations      | 64 (46)        |
| Proteinuria (present/absent) (mean ± SD) | 20/110 (49.70 ± 4.21) ranges between 0.9–127 mg/m²/h |
| Proteinuria (non-nephrotic/nephrotic) | 13/16 |
| Hematuria (present/absent)  | 59 (20 macroscopic; 39 microscopic)/80 |
| Nephrotic syndrome        | 5 (12%)        |
| Renal insufficiency       | 3 (4%)         |

Table 2  
The allele and genotype frequencies of the ACE I/D Polymorphism both in patients and healthy controls

| ACE I/D Polymorphism | Clinically diagnosed HSP patients group (n:139) | Healthy control group (n:72) | \( \chi^2 \) | p value | OR (95% CI) |
|----------------------|-------------------------------------------------|-----------------------------|-----------|----------|-------------|
| Genotypes            |                                                 |                             |           |          |             |
| II                   | 20 (14.4%)                                      | 20 (27.8%)                  | 11.313    | 0.003    | ID-DD vs. II|
| ID                   | 58 (44.7%)                                      | 36 (50.0%)                  |           |          |             |
| DD                   | 61 (43.9%)                                      | 16 (22.2%)                  |           |          |             |
| Alleles (2N)         |                                                 |                             |           |          |             |
| I                    | 98 (35.3%)                                      | 76 (52.8%)                  | 12.025    | 0.001    | D vs. I     |
| D                    | 180 (64.7%)                                     | 68 (47.2%)                  |           |          |             |

The PCR product was digested with restriction enzyme Thh111 I (New England Biolabs, UK) to identify the M > T polymorphism at 37°C for 16 h. Digested DNA fragment products were separated by electrophoresis on 2% agarose gel and visualized by ethidium bromide staining. The presence of uncut 165 bp fragment band indicated MM, 141 (cleaved) + 24 bp fragment band indicated TT, and 165 + 141 + 24 fragment band indicated MT heterozygous genotype (Fig. 2).

2.3. Statistical analysis

All statistical analyses were performed with the SPSS 13.0 statistical program. Hardy-Weinberg equilibrium was assessed by chi-square goodness-of-fit test. Comparison of the genotypic and allelic frequencies between the groups was performed using the Fisher exact test or Chi-square test when appropriate. Logistic regression analysis was used to identify odds ratios (OR) and 95% confidence intervals (CI) to determine whether association exists between genotypes and the risk of developing HSP in patients as compared to the control samples. A two tailed p value < 0.05 was considered as statistically significant.

3. Results

The present study group included 139 clinically diagnosed HSP (77 males/62 females; ages range from 2 to 17 years; female/male ratio was 1.2:1) patients and ethnically matched healthy control individuals with no renal, vasculitic, or allergic diseases and no vasculitis/rheumatologic and other kidney disease history in family included 72 (49 females/23 males; ages range from 18 to 45 years) for ACE gene, and 87 (57 females/30 males; ages range from 18 to 45 years) for AGT gene. The demographic and clinical characteristics of the subjects have been summarised in Table 1. Mean disease onset of the patients who had been on follow-up for at least 6 months was 8.6 ± 3.1 years (Table 1). Patients had been followed up for a mean of 8.2 ± 7.5 months and for at least 6 months for kidney involvement. Skin, joint, GIS, and renal involvements and presence of hematuria, proteinuria, hypertension, and central nervous system at the time of diagnosis and follow-up were shown in Table 1. End stage renal disease was not determined in any patients, hence, hematuria, proteinuria, renal function disorder, and factors effecting those were investigated at follow-up. No
Table 3

The distribution of the genotype and allele frequencies of ACE I/D Polymorphism in association with main clinical features of 139 children with HSP

| ACE I/D Polymorphism | Renal n (%) | Joint n (%) | GIS n (%) | Controls (n:72) |
|----------------------|------------|------------|-----------|----------------|
|                      | Absence    | Presence   | Absence   | Presence       |
| II                   | 6 (30%)    | 14 (70%)   | 8 (40%)   | 12 (60%)       |
| ID                   | 35 (60.3%) | 23 (39.7%) | 26 (44.8%)| 32 (55.2%)     |
| DD                   | 34 (55.7%) | 27 (44.3%) | 26 (42.6%)| 35 (57.4%)     |
| χ²                   | 5.651      | 0.154      | 5.651     |
| p value              | 0.059      | 0.926      | 0.059     |
| Alleles (2N)         |            |            |           |                |
| I                    | 47 (48%)   | 51 (52%)   | 42 (41.6%)| 59 (58.4%)     |
| D                    | 103 (57.2%)| 77 (42.8%) | 78 (43.3%)| 102 (56.7%)    |
| χ²                   | 2.192      | 0.081      | 2.600     |
| p value              | 0.139      | 0.776      | 0.107     |
| OR (95% CI) I vs D   | 0.689 (0.420–1.129) | 0.931 (0.568–1.525) | 0.667 (0.407–1.092) |

The frequency of the D allele in patients group (64.7%) was significantly higher than in healthy controls (47.2%). Risk assessment showed that individuals possessing an ACE D allele had an increased risk of HSP (odds ratio: D vs. I: 2.0528, 95% CI: 1.3632 to 3.0912, p = 0.001). The presence of D allele carries a 2.05-fold increased risk for HSP relative to the I allele (95% CI: 1.3632 to 3.0912, p = 0.001).

In order to evaluate the exact effect of ACE I/D polymorphism on various complications of the disease, we performed genotype-phenotype correlations, but no statistically significant differences between HSP patients and HSP nephritis,

Table 4

The allele and genotype frequencies of the AGT M/T polymorphism both in patients and healthy controls

| AGT M/T Polymorphism | Clinically diagnosed HSP patients group (n:139) | Healthy control group (n: 87) | χ² | p value | OR (95% CI) |
|----------------------|-----------------------------------------------|-------------------------------|----|---------|-------------|
|                      |                                               |                               |    |         |             |
| Genotype             |                                               |                               |    |         |             |
| MM                   | 37 (26.6%)                                     | 18 (20.7%)                    | 4.891 | 0.087  | MT/TT vs. MM |
| MT                   | 59 (42.4%)                                     | 50 (57.5%)                    |     |         | OR: 0.7192 |
| TT                   | 43 (30.9%)                                     | 19 (21.8%)                    |     |         | 95% CI: 0.3789–1.365 |
| Allele               |                                               |                               |    |         |             |
| M                    | 133 (47.8%)                                    | 86 (49.4%)                    | 0.107 | 0.743  | T vs. M:    |
| T                    | 145 (52.2%)                                    | 88 (50.6%)                    |     |         | OR: 1.065, 95% CI: 0.729–1.557 |

The overall distribution of the ACE I/D polymorphism genotypes and alleles differed significantly between the patients group and healthy controls (p = 0.003, and p = 0.001, respectively). This was reflected in increases in the frequency of the D allele, and the homozygote DD genotype in patients group (64.7%, and 43.9%).

Patients with ID+DD genotypes had a higher risk of developing HSP compared to patients with II genotype (ID+DD vs. II: χ²: 5.535, p = 0.019; OR: 2.288, 95% CI: 1.136–4.609).

Furthermore, the DD genotype was associated with a 2.7-fold increased risk for HSP compared to patients with II+ID genotype (χ²: 9.604, p: 0.002, OR = 2.737, 95% CI = 1.431–5.237).

The frequency of the D allele in patients group (64.7%) was significantly higher than in healthy controls (47.2%). Risk assessment showed that individuals possessing an ACE D allele had an increased risk of HSP (odds ratio: D vs. I: 2.0528, 95% CI: 1.3632 to 3.0912, p = 0.001). The presence of D allele carries a 2.05-fold increased risk for HSP relative to the I allele (95% CI: 1.3632 to 3.0912, p = 0.001).

In order to evaluate the exact effect of ACE I/D polymorphism on various complications of the disease, we performed genotype-phenotype correlations, but no significant association was found between the absence and presence of different organ involvements and the ACE I/D polymorphism. No statistically significant differences between HSP patients and HSP nephritis,
The distribution of the genotype and allele frequencies of AGT M/T polymorphism in association with main clinical features of 139 children with HSP

| Genotypes | Renal n (%) | Joint n (%) | GIS n (%) | Controls (n:87) |
|-----------|-------------|-------------|-----------|----------------|
|           | Absence     | Presence    | Absence   | Presence       |
| MM        | 15 (40.5%)  | 22 (59.5%)  | 13 (35.1%)| 24 (64.9%)     | 18 (48.6%) | 19 (51.4%) | 18 (20.7%) |
| MT        | 35 (59.3%)  | 24 (40.1%)  | 28 (47.5%)| 31 (52.5%)     | 24 (35.6%)| 25 (42.4%)| 50 (57.5%) |
| TT        | 25 (58.1%)  | 18 (41.9%)  | 19 (44.2%)| 24 (55.8%)     | 23 (53.5%)| 20 (46.5%)| 19 (21.8%) |
| χ²        | 3.667       | 1.434       |           |               |
| p value   | 0.160       | 0.488       |           |               |
| Alleles (2N) |          |             |           |               |
| M         | 65 (48.9%)  | 68 (51.1%)  | 54 (40.6%)| 79 (59.4%)     | 70 (52.6%)| 63 (47.4%)| 86 (49.4%) |
| T         | 85 (58.6%)  | 60 (41.4%)  | 66 (45.5%)| 79 (54.5%)     | 80 (55.2%)| 65 (44.8%)| 88 (50.6%) |
| χ²        | 2.654       | 0.683       |           |               |
| p value   | 0.103       | 0.408       |           |               |
| OR (95% CI) | M vs T    |             |           |               |
|           | 0.675 (0.420–1.084) | 0.818 (0.508–1.317) | 0.903 (0.563–1.448) |

with or without renal, gastrointestinal manifestations, and arthritis, hypertension or CNS were observed (p > 0.05) (Table 3). No significant correlation was detected between ACE I/D polymorphism and epidemiological (age and sex) features (p > 0.05). Presence of D allele did not show a risk factor for clinical characteristics (p > 0.05). The distribution of the genotype and allele frequencies of ACE I/D polymorphism in association with clinical characteristics of the HSP patients were given in Table 3.

Genotype analysis of the AGT M/T polymorphism did not reveal a significant deviation from Hardy-Weinberg equilibrium in any group. The allele and genotype frequencies of the AGT M/T polymorphism both in patients and healthy controls were reported in Table 2. Three genotypes (MM, MT, and TT) of AGT M/T polymorphism were found in the patients and controls. Distribution of AGT M/T polymorphism genotypes and alleles in patients and controls were as follows: in the patients group, 26.6% of them were genotype MM, 42.4% were genotype MT, and 30.9% were genotype TT whereas in the healthy control group, 20.7% of the individuals were genotype MM, 57.5% were genotype MT, and 21.8% were genotype TT. M allele frequency was 47.8% and 49.4% in the patients group and the healthy control group, respectively, whereas T allele frequency was 52.2% and 50.6% in the patients and the healthy control group, respectively (Table 4).

The overall distribution of the AGT M/T polymorphism genotypes and alleles did not differ significantly between the patients group and healthy controls (p = 0.087, and p = 0.743, respectively). The frequencies of homozygote TT genotype (30.9%) and T allele (52.2%) were higher in patients than in controls, however the result was insignificant. Patients with MT/TT genotypes did not have a higher risk of developing HSP compared to patients with MM genotype (χ²: 1.022, p = 0.312, OR: 0.7192, 95% CI: 0.3789–1.365). Furthermore, patients with TT genotype (χ²: 2.224, p = 0.136, OR: 0.6238, 95% CI: 0.3346 to 1.163) and T allele (odds ratio: T vs. M: 1.065, 95% CI: 0.729 to 1.557, p = 0.743) did not have a higher risk of developing HSP compared to patients with MM+MT genotype.

In order to evaluate the exact effect of polymorphism on various complications of the disease, we performed genotype-phenotype correlations, but no significant association was found between the absence and presence of different organ involvements and the AGT M/T polymorphism. No statistically significant differences between HSP patients and HSP nephritis, with or without renal, gastrointestinal manifestations, and arthritis, hypertension or CNS were observed (p > 0.05). No significant correlation was detected between AGT M/T polymorphism and epidemiological (age and sex) features (p > 0.05). Presence of T allele did not show a risk factor for clinical characteristics (p > 0.05). The distribution of the genotype and allele frequencies of AGT M/T polymorphism in association with clinical characteristics of the HSP patients were given in Table 4.

4. Discussion

Present study investigated the genetic association between HSP and RAS polymorphisms involving I/D polymorphism of the ACE gene, and M235T polymorphism of the AGT gene. HSP patients who were homozygous for the deletion allele (DD) presented a significantly higher prevalence of HSP compared to patients homozygous for the insertion allele (II) or het-
erozygous (ID). Conversely, no association was found between HSP and the M235T polymorphism of the AGT gene. The association between DD genotype/D allele and HSP was consistent as shown by a high odds ratio, but the genotype-phenotype correlation analysis showed no significant association between ACE I/D, AGT M235T, and main clinical manifestations of HSP.

To date, a number of gene loci have been reported to contribute to the susceptibility and pathogenesis of HSP, such as the human leukocyte antigen (HLA) complex. HLA Class III region genotype C4B was associated with HSP in Caucasians [35], Korean [36], and Japanese [37] patients. Also, HLA Class II genes were indicated as genetic risk factors for HSP nephritis in Japanese patients (genotype DQA1*0301) [37], and in Italian patients (DRB1*01 or DRB1*11) [38]. HLA-DRB1 11/14 in Turkish children [39] and HLA-DRB1*13 genotype in Turkish patients in another study of the same group were related to the susceptibility of HSP [40]. HLA-DRB1*01 [41] and HLA-B35 [42] were associated to susceptibility of HSP in patients from northwest Spain. HLA class 1 alleles -HLA A2, A11, and B35- were considered as risk factors for developing HSP [43]. Also, HLA-A*111*1301 and -B*1501 were associated with susceptibility to HSP in Mongolian children and HLA-A*2601, HLA-B*3503 and HLA-B*52 were associated with susceptibility to HSP in Han children [44]. Role of chemotactic inflammatory markers such as IL-1RA, IL-6, IL-8, IL-13 [45–49], eNOS— which is the major mediator in the regulation of vascular homeostasis, and MIF [50–52] were also previously demonstrated in HSP and relevant vascular disorders. As it has been previously stated, HSP is known to occur via vascular injuries by inflammatory reaction and immunologic activation. Therefore, we hypothesized that vascular development of HSP might have been related to the D and T alleles of the respective RAS genes. Accordingly, we obtained a relationship between ACE and HSP, however genetic association between AGT M235T and HSP pathogenesis was not detected. Moreover, possession of the polymorphic alleles of either ACE I/D or AGT M235T polymorphisms did not seem to have an impact on the development of gastric, renal, and articular manifestations of the disease, meaning that absence or presence of various organ involvement were found unrelated to any genotypes and/or alleles in the analysed polymorphisms. In contrast, Zhou et al. [53] and Liu et al. [54] significantly associated RAS gene polymorphisms (ACE-I/D and AGT M235T) with susceptibility to HSP, HSPN, organ involvement, and disease severity, although conflicting data exist [55,56]. Similarly, Ozkaya et al. evidenced the relationship between AGT M235T and HSPN [57]. Different from Ozkaya et al.’s study conducted on Turkish patients, current work involved the association of genotypes and alleles with other clinical manifestations except for the renal involvement. However, even though there was a trend toward higher DD genotype frequency in patients with renal involvement across the healthy controls (44.3 vs. 22.2%), results were not statistically significant ($p > 0.05$). This was also the case when comparing patients with gastric (44.3 vs. 22.2%) and articular (57.4 vs. 22.2%) involvements across the healthy controls ($p > 0.05$). The same was evident for AGT M235T polymorphism which was found unrelated to the HSP susceptibility due to insignificant difference in the allele frequencies and genotype distributions among cases and controls. The lack of association between AGT M235T and HSP may be due to a loss of power which was 0.01, whereas it was 0.95 for the ACE I/D polymorphism that already showed significant association. Regarding the current and the recent [57] polymorphism studies conducted on Turkish patients, the discrepancy in the association of AGT M235T with HSP may be due to relatively small number of patients enrolled in the current study in terms of genetic epidemiology studies. Moreover, patients enrolled in the current study were mostly from Western region of Turkey while Ozkaya et al examined patients mostly from Northern region of Turkey. In case-control polymorphism studies, distribution of polymorphic alleles may have been affected by racial and regional factors, population heterogeneity due to selection of subjects from different regions, and possible unidentified polymorphisms in RAS which contribute to inter-individual differences in susceptibility to disease.

In previous reports, D allele was associated with increased ACE activity in the vessel wall leading to vascular inflammation [27–31]. The presence of D allele was found to carry a 2.05-fold increased risk for HSP relative to the I allele (95% CI: 1.3632 to 3.0912, $p = 0.001$) whereas there was not a significant risk for HSP in the subjects both with the TT genotype ($p = 0.087$, MT/TT vs. MM, OR:0.7192, 95% CI: 0.3789–1.365), and the T allele ($p = 0.743$, T vs. M, OR: 1.065, 95% CI: 0.729–1.557). Thus, this may be attributed to the dysregulation of vascular homeostasis and inflammation in “D” allele carriers leading to vasculitis of the small blood vessels, and endothelial cell activation, however further studies are required to estimate circulating ACE enzyme levels in patients with HSP.
In the present study, we also compared genotype frequencies of the healthy population with the previously published data on other populations. The frequency of the ACE I/D DD genotype (22.2%) in our control Turkish population was lower than that reported in German (26.8%) and Italian (42%) populations [55,58], but higher than Taiwan Chinese population (18%) [59]. Our data was in striking contrast to the results of previously reported on Italian population [55], but similar to the results of other studies on Chinese [59], German [58] and South Indian [60] populations. Also, previously reported DD genotype frequencies of Turkish population by different study groups were 11.6% [57], 30% [61], 58% [62], and 60% [63] all of which were different from that reported in the current study (22.2%). Regarding AGT M/T polymorphism, the frequency of TT genotype (21.8%) in our control Turkish population was lower than that reported in South Indian (44.8%) population [60], but higher than German population (4.6%) [58]. Other studies conducted on Turkish population identified TT genotype frequency as 48% [63], and 7.9% [57] which were in striking contrast to the results reported on the current Turkish population (21.2%). The inconsistency in the distribution of ACE I/D and AGT M/T polymorphism genotypes between these studies may be due to various sampling sizes and ethnic differences or different ancestries in different regions of the same country populations.

In conclusion, our findings suggest that AGT M235T polymorphism does not seem to contribute to the susceptibility and/or certain systemic manifestations of HSP, while ACE I/D polymorphism confers a significantly increased risk for susceptibility to HSP in the present Turkish population. Nonetheless, due to ethnic variations among restricted populations, polymorphisms in the respective genes have been frequently associated inconsistently with vascular pathologies, and association studies between RAS and HSP/HSPN have been limited and conflicting, thus underlying genetic pathways of HSP still remain elusive. Search for possible candidate genes and different pathogenic mechanisms in the development of HSP in patients with various genetic backgrounds are required to fully eliminate the potential role of these polymorphisms in the pathogenesis of HSP.

Acknowledgements

We would like to thank all the patients and clinicians for participating in this study, and Hatice Uluer for valuable contributions to the statistical analyses. No Disclosure Statement. No competing financial interests exist.

References

[1] D’Arsigny C, Small vessel vasculitides and the pulmonary-renal syndrome, Out Thoracic Rev. (2006) 18(3): 1, 4-7.
[2] Gedalia A, Heno–Schönlein purpura, Curr Rheumatol Rep. (2004) 6: 195-202.
[3] Tizard EJ, Hamilton-Ayres MJ, Heno–Schönlein purpura, Arch Dis Child Educ Pract Ed. (2008) 93: 1-8.
[4] Ballinger S, Heno–Schönlein purpura, Curr Opin Rheumatol. (2008) 15: 591-594.
[5] Leung DY, Immunologic aspects of Kawasaki syndrome, J Rheumatol Suppl. (1990) 24: 15-18.
[6] Cohen TJ, Kallenberg CG, Vasculitis, Klinische Immunologie, edited by the TH, De Kallenberg CGM, Leij L. Houten/Antwerpen: Bohn Stafleu Van Loghum. (1991) pp. 216-233.
[7] Riazzada V, Skipper B, Luo W, Griffith J. Intracardiac and intrarenal renin – angiotensin systems: Mechanisms of cardiovascular and renal effects. J Investig Med. (2007) 55: 341-59.
[8] Cheng ZJ, Vapaatalo H, Mervaala E. Angiotensin II and vascular inflammation. Med Sci Monit. (2005) 11: 194-205.
[9] Soubrier F, Alhenc-Gelas F, Hubert C, Allegreni J, John M et al. Two putative active centers in human angiotensin I-converting enzyme revealed by molecular cloning. Proc Natl Acad Sci U S A. (1988) 85(24): 9386-9390.
[10] Gaillard I, Clauser E, Corvol P. Structure of the human angiotensinogen gene. DNA. (1989) 8(2): 87-99.
[11] Takayanagi R, Ohnaka K, Sakai Y, Nakao R, Yanase T et al. Molecular cloning, sequence analysis and expression of a cDNA encoding human type-I angiotensin II receptor. Biochem Biophys Res Commun. (1992) 183(2): 910-916.
[12] Mattei MG, Hubert C, Alhenc-Gelas F, Roeckel N, Corvol P, Soubrier F. Angiotensin-I converting enzyme gene is on chromosome 17. Cytogeten Cell Genet. (1989) 51: 1041.
[13] Kaufman KM, Kelly J, Gray-McGuire C, Asundi N, Yu H, Reid J, Baird T, Hutchings D, Bruner G, Scolfield RH, Moser K, Harley JB. Linkage analysis of angiotensin-converting enzyme (ACE) insertion/deletion polymorphism and systemic lupus erythematosus. Mol Cell Endocrinol. (2001 May 25) 177(1-2): 81-5.
[14] Uhlm WS, Lee HS, Chung YH, Kim TH, Bae SC, Joo KB, Kim TY, Yoo DH. Angiotensin-converting enzyme gene polymorphism and vascular manifestations in Korean patients with SLE. Lupus. (2002) 11: 227-233.
[15] Staessen JA, Wang JG, Ginooccio G, Petrov V, Saavedra AP, Soubrier F, Vlieitnck R, Fagard R: The deletion/insertion polymorphism of the angiotensin converting enzyme gene and cardiovascular-renal risk. J Hypertens. (1997) 15: 1579-1592.
[16] Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest. (1990) 86(4): 1343-6.
[17] Lindpaintner K, Pfeffer MA, Kreutz R, Stampfer MJ, Grodstein F, LaMotte F, et al. A prospective evaluation of an angiotensin-converting-enzyme gene polymorphism and the risk of ischemic heart disease. N Engl J Med. (1995) 16: 332(11): 706-11.
C4 phenotypes in IgA nephropathy and Henoch-Schönlein purpura. Kidney Int. (1984) 26(6): 855-60.

[36] Jin DK, Kohsaka T, Koo JW, Ha IS, Cheong HL, Choi Y. Complement 4 locus II gene deletion and DQA1*0301 gene: genetic risk factors for IgA nephropathy and Henoch-Schönlein nephritis. Nephron. (1996) 73(3): 305-9.

[37] Abe J, Kohsaka T, Tanaka M, Kobayashi N. Genetic study on HLA class II and class III region in the disease associated with IgA nephropathy. Nephron. (1993) 65(1): 17-22.

[38] Amoroso A, Berrino M, Canale L, Coppo R, Corniglia M, Guarrera S, Mazzola G, Scolari F. Immunogenetics of Henoch-Schönlein disease. Eur J Immunogenet. (1997) 24(5): 323-33.

[39] Amoli MM, Thomson W, Hajeer AH, Calviño MC, Garcia-Porrua C, Ollier WE, Gonzalez-Gay MA. HLA-DRB1*01 association with Henoch-Schönlein purpura in patients from northwest Spain. J Rheumatol. (2008) 35(6): 1165-8. Epub 2008 Apr 15.

[40] Amoli MM, Thomson W, Hajeer AH, Calviño MC, Garcia-Porrua C, Ollier WE, Gonzalez-Gay MA. HLA-B35 association with nephritis in Henoch-Schönlein purpura. J Rheumatol. (2002) 29(5): 948-9.

[41] Amoli MM, Martin J, Miranda-Filloy JA, Garcia-Porrua C, Ollier WE, Gonzalez-Gay MA. HLA-DRB1*01 association with severe renal involvement and renal sequelae in Henoch-Schönlein Purpura, J Rheumatol. (2001) 28(6): 1266-70.

[42] Amoli MM, Thomson W, Hajeer AH, Calviño MC, Garcia-Porrua C, Ollier WE, Gonzalez-Gay MA. HLA-B35 association with nephritis in Henoch-Schönlein purpura. J Rheumatol. (2002) 29(5): 948-9.

[43] Amoli MM, Thomson W, Hajeer AH, Calviño MC, Garcia-Porrua C, Ollier WE, Gonzalez-Gay MA. Lack of association between interleukin-6 promoter polymorphism at position −174 and Henoch-Schönlein purpura. Clin Exp Rheumatol. (2007) 25(1 Suppl 44): S6-9.

[44] Amoli MM, Thomson W, Hajeer AH, Calviño MC, Garcia-Porrua C, Ollier WE, Gonzalez-Gay MA. Lack of association between macrophage migration inhibitory factor gene (−173 G/C)
polymorphism and cutaneous vasculitis, Clin Exp Rheumatol. (2006) 24(5): 576-9.

[51] Dursun A, Durakbasi-Dursun HG, Dursun R, Baris S, Akduman L. Angiotensin-converting enzyme gene and endothelial nitric oxide synthase gene polymorphisms in Behçet’s disease with or without ocular involvement. Inflamm Res. (2009).

[52] Kim JU, Chang HK, Lee SS, Kim JW, Kim KT, Lee SW, Chung WT. Endothelial nitric oxide synthase gene polymorphisms in Behçet’s disease and rheumatic diseases with vasculitis. Ann Rheum Dis. (2003) 62(11): 1083-7.

[53] Zhou J, Tian X, Xu Q. Angiotensin-converting enzyme gene insertion/deletion polymorphism in children with HSP nephritis. J Huazhong Univ Sci Technolog Med Sci. (2004) 24(2): 158-61.

[54] Desong Liu, Fang Lu, Songhui Zhai, Liu Wei, Shi Ma, Xiuying Chen, Liqun Dong, Yannan Guo, Jin Wu, Zheng Wang. Renin-angiotensin system gene polymorphisms in children with Henoch-Schönlein purpura in West China. J Renin Angiotensin Aldosterone Syst. (2010) 11(4): 248-55.

[55] Amoroso A, Danek G, Vatta S, Crovella S, Berrino M, Guarerra S, Fasano ME, Mazzola G, Amore A, Gianoglio B, Peruzzi L, Coppo R. Polymorphisms in angiotensin-converting enzyme gene and severity of renal disease in Henoch-Schönlein patients. J Renin Angiotensin Aldosterone Syst. (2010) 11(4): 248-55.

[56] Dudley J, Afifi E, Gardner A, Tizard EJ, McGraw ME. Polymorphism of the ACE gene in Henoch-Schönlein purpura nephritis. Pediatr Nephrol. (2000) 14(3): 218-20.

[57] Ozkaya O, Stylenmezoglu O, Gonen S, Misirlioglu M, Tuncer S, Kalman S, Buyan N, Hasanoğlu E. Renin-angiotensin system gene polymorphisms: association with susceptibility to Henoch-Schönlein purpura and renal involvement. Clin Rheumatol. (2006) 25(6): 861-5.

[58] Mondry A, Loh M, Liu P, Zhu AL, Nagel M. Polymorphisms of the insertion/deletion ACE and M235T AGT genes and hypertension: Surprising new findings and meta-analysis of data. BMC Nephrol. (2005) 6:1.

[59] Chou HT, Tsai CH, Tsai FJ. Association between angiotensin I-converting enzyme gene insertion/deletion polymorphism and risk of rheumatic heart disease. Jpn Heart J. (2004) 45(6): 949-57.

[60] Ramu P., G. Umamaheswaran, D.G. Shewade, R.P. Swaminathan, T.K. Dutta, J. Balachander and C. Adithan. Candidate Gene Polymorphisms of Renin Angiotensin System and Essential Hypertension in a South Indian Tamilian Population International Journal of Human Genetics. (2011) 11(1): 31-40.

[61] Oztürk MA, Calğäneri M, Kiraz S, Ertenli I, Onat AM, Ureten K, Ozbalkan Z, Haznedaroğlu IC. Angiotensin-converting enzyme gene polymorphism in Behçet’s disease. Clin Rheumatol. (2004) 23(2): 142-6. Epub 2004 Feb 24.

[62] Turgut S, Turgut G, Atalay EO, Atalay A. Angiotensin-converting enzyme I/D polymorphism in Behçet’s disease. Med Princ Pract. (2005) 14: 213-6.

[63] Güürkän A, Emingil G, Saygan BH, Atilla G, Köse T, Baylas H, Berdeli A. Angiotensin-converting enzyme (ACE), angiotensinogen (AGT), and angiotensin II type 1 receptor (AT1R) gene polymorphisms in generalized aggressive periodontitis. Arch Oral Biol. 2009; 54(4): 337-44. Epub 2009 Jan 21.